SOPHiA GENETICS SA (SOPH) fair value analysis
Nasdaq · Updated 2026-10-19
SOPH price how computed
Valuation status
No fair-value estimate yetSOPH has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for SOPH yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $6.73
- Sector
- Healthcare
- 12-month range
- $3.89–$8.92
- Market cap
- $573M
- From 52-week high
- -24.6%
- Shares outstanding
- 85.1M
- Rank in Healthcare by quality score
- #160 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
SOPHiA GENETICS SA is a healthcare company that develops artificial intelligence and genomics software solutions designed to interpret genetic data and support clinical decision-making. The company operates internationally and is listed on the Nasdaq stock exchange.
SOPH currently ranks #160 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $573M
- P/E (trailing)
- n/m
- Revenue (TTM)
- $86.2M
- Net margin
- -93.9%
- EPS (TTM)
- $-0.82
- Gross margin
- 64.6%
- Debt / equity
- 0.74
- Revenue growth (3-yr avg)
- 14.3%
- Shares outstanding
- 85.1M
Derived indicators how computed
- Quality grade
- D
- Margin trend
- Contracting
- 52-week position
- The upper-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 28 · oversold
- 50-day average
- $7.95
- 200-day average
- $5.83
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-11-03
- Last 8 quarters vs consensus
- 4 beat, 3 missed
- Quarter by quarter
- 2026-06 ▼ miss (-73.3%)
2026-03 ▲ beat (+20.8%)
2025-12 ▲ beat (+22.4%)
2025-09 ▬ met (0.0%)
2025-06 ▼ miss (-47.1%)
2025-03 ▲ beat (+5.3%)
2024-12 ▲ beat (+20.1%)
2024-09 ▼ miss (-16.7%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 5 buy · 0 hold · 0 sell (5 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $9.75
- Target vs last price
- +44.9%
What our data shows for SOPH
- Shares are trading in the middle of their 12-month price range of $3.89–$8.92.
- The 14-day relative strength index sits at an oversold 28.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- SOPH's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the SOPH conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — SOPH's Relative Strength Index moved into oversold territory this week, shifting from a neutral zone in the previous period. The Healthcare sector stock's technical momentum indicator now reflects a change in short-term price pressure dynamics. The company's full valuation assessment remains pending as of this reporting period.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — SOPH's 50/200-day trend state shifted from uptrend to mixed during the week, reflecting a change in TickrTrends' derived indicators. The stock remains within the Healthcare sector with a valuation verdict currently awaiting full valuation assessment.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is SOPH stock undervalued?
TickrTrends has no fair-value estimate for SOPH yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is SOPH's TickrTrends verdict?
SOPH is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does SOPH compare to other Healthcare stocks?
SOPH ranks #160 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is SOPH overbought or oversold?
SOPH's 14-day RSI is in the oversold zone on TickrTrends' latest weekly data.
When does SOPH report earnings next?
SOPH's next earnings report is scheduled for 2026-11-03, per the published earnings calendar.
Does SOPH usually beat earnings estimates?
Over its last 8 reported quarters SOPH beat the consensus estimate 4 times and missed 3 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about SOPH?
Of 5 analysts covering SOPH, 5 rate it a buy, 0 a hold and 0 a sell - buy-leaning, with a consensus price target of $9.75 (+44.9% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.